Quoin Pharmaceuticals Ltd. SEC filings QNRX
Quoin Pharmaceuticals Ltd. has 583 filings in SEC EDGAR's recent list, going back to Apr 8, 2016. Its latest annual report, Form ARS, was filed on Jul 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (material agreement).
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Nov 4, 2026 | — |
| 424B5 | Prospectus supplement | Nov 4, 2026 | — |
| S-3 | Shelf registration | Oct 28, 2026 | — |
| 424B3 | Prospectus | Sep 25, 2026 | — |
| S-3 | Shelf registration | Sep 18, 2026 | — |
| 424B3 | Prospectus | Jun 2, 2026 | — |
| 424B3 | Prospectus | Dec 5, 2025 | — |
| S-3 | Shelf registration | Nov 7, 2025 | — |
| S-8 | Employee stock plan registration | Aug 27, 2025 | — |
| S-8 | Employee stock plan registration | Aug 25, 2025 | — |
| POS AM | Filing | Mar 28, 2025 | — |
| 424B4 | Prospectus | Dec 23, 2024 | — |
| S-1/A | Amended registration statement | Dec 18, 2024 | — |
| S-1 | Registration statement | Dec 11, 2024 | — |
| 424B3 | Prospectus | Dec 11, 2024 | — |
| 424B3 | Prospectus | Nov 8, 2024 | — |
| 424B3 | Prospectus | Aug 12, 2024 | — |
| 424B3 | Prospectus | May 10, 2024 | — |
| 424B3 | Prospectus | May 8, 2024 | — |
| POS AM | Filing | Mar 29, 2024 | — |
| 424B3 | Prospectus | Mar 8, 2024 | — |
| 424B3 | Prospectus | Mar 8, 2024 | — |
| 424B4 | Prospectus | Mar 6, 2024 | — |
| 424B3 | Prospectus | Mar 4, 2024 | — |
| S-1/A | Amended registration statement | Feb 13, 2024 | — |
| S-1 | Registration statement | Feb 12, 2024 | — |
| 424B3 | Prospectus | Jan 31, 2024 | — |
| 424B3 | Prospectus | Dec 18, 2023 | — |
| 424B3 | Prospectus | Nov 9, 2023 | — |
| 424B3 | Prospectus | Nov 7, 2023 | — |
| 424B3 | Prospectus | Nov 1, 2023 | — |
| 424B3 | Prospectus | Sep 14, 2023 | — |
| 424B3 | Prospectus | Aug 3, 2023 | — |
| 424B3 | Prospectus | Jul 18, 2023 | — |
| 424B3 | Prospectus | Jun 28, 2023 | — |
| 424B3 | Prospectus | May 12, 2023 | — |
| 424B3 | Prospectus | May 9, 2023 | — |
| 424B3 | Prospectus | Apr 7, 2023 | — |
| 424B3 | Prospectus | Mar 22, 2023 | — |
| POS AM | Filing | Mar 15, 2023 | — |
| S-8 | Employee stock plan registration | Mar 15, 2023 | — |
| 424B3 | Prospectus | Feb 28, 2023 | — |
| 424B3 | Prospectus | Feb 28, 2023 | — |
| 424B3 | Prospectus | Feb 28, 2023 | — |
| 424B4 | Prospectus | Feb 23, 2023 | — |
| S-1/A | Amended registration statement | Feb 9, 2023 | — |
| S-1 | Registration statement | Feb 3, 2023 | — |
| 424B3 | Prospectus | Nov 10, 2022 | — |
| 424B3 | Prospectus | Nov 10, 2022 | — |
| 424B3 | Prospectus | Nov 7, 2022 | — |
| 424B3 | Prospectus | Nov 7, 2022 | — |
| 424B3 | Prospectus | Oct 28, 2022 | — |
| 424B3 | Prospectus | Oct 28, 2022 | — |
| 424B3 | Prospectus | Sep 21, 2022 | — |
| 424B3 | Prospectus | Sep 21, 2022 | — |
| 424B3 | Prospectus | Aug 18, 2022 | — |
| 424B3 | Prospectus | Aug 18, 2022 | — |
| 424B3 | Prospectus | Aug 11, 2022 | — |
| 424B3 | Prospectus | Aug 11, 2022 | — |
| 424B4 | Prospectus | Aug 9, 2022 | — |
| F-1MEF | Filing | Aug 5, 2022 | — |
| F-1/A | Filing | Aug 4, 2022 | — |
| F-1 | Registration statement (foreign issuer) | Aug 3, 2022 | — |
| 424B3 | Prospectus | Jul 15, 2022 | — |
| 424B3 | Prospectus | Jun 17, 2022 | — |
| F-3 | Shelf registration (foreign issuer) | Jun 14, 2022 | — |
| 424B3 | Prospectus | Jun 13, 2022 | — |
| 424B3 | Prospectus | Jun 6, 2022 | — |
| 424B3 | Prospectus | May 23, 2022 | — |
| 424B3 | Prospectus | Apr 28, 2022 | — |
| 424B3 | Prospectus | Apr 26, 2022 | — |
| F-1 | Registration statement (foreign issuer) | Apr 15, 2022 | — |
| F-4/A | Filing | Aug 10, 2021 | — |
| F-4/A | Filing | Aug 6, 2021 | — |
| F-4/A | Filing | Jul 16, 2021 | — |
| F-4 | Filing | Jun 16, 2021 | — |
| 424B3 | Prospectus | May 12, 2020 | — |
| 424B5 | Prospectus supplement | Jan 10, 2020 | — |
| S-8 | Employee stock plan registration | Jun 20, 2019 | — |
| POS AM | Post-effective amendment no. 1 to form f-1 | Mar 26, 2019 | — |
| 424B4 | Prospectus | Feb 11, 2019 | — |
| F-1/A | Amended to registration statement | Feb 7, 2019 | — |
| F-1/A | Amendment no. 1 to form f-1 | Jan 24, 2019 | — |
| F-1 | Registration statement (foreign issuer) | Dec 28, 2018 | — |
| POS AM | Post-effective amendment no. 2 to form f-1 | Aug 9, 2018 | — |
| S-8 | Employee stock plan registration | May 17, 2018 | — |
| POS AM | Post-effective amendment to form f-1 | Mar 21, 2018 | — |
| 424B3 | Prospectus | Feb 9, 2018 | — |
| F-1/A | Amendment no. 1 to form f-1 | Feb 6, 2018 | — |
| 424B5 | Prospectus supplement | Jan 31, 2018 | — |
| F-1 | Registration statement (foreign issuer) | Dec 28, 2017 | — |
| 424B5 | Prospectus supplement | Sep 7, 2017 | — |
| S-8 | Employee stock plan registration | Aug 17, 2017 | — |
| POS AM | Post-effective amendment no. 2 | Aug 1, 2017 | — |
| F-3 | Shelf registration (foreign issuer) | Aug 1, 2017 | — |
| POS AM | Filing | Mar 30, 2017 | — |
| S-8 | Employee stock plan registration | Nov 28, 2016 | — |
| 424B4 | Prospectus | Aug 1, 2016 | — |
| F-1/A | Filing | Jul 28, 2016 | — |
| F-1/A | Filing | Jul 27, 2016 | — |
| F-6 | Form f-6 | Jul 27, 2016 | — |
| F-1/A | Filing | Jul 26, 2016 | — |
| FWP | Free writing prospectus | Jul 25, 2016 | — |
| F-1/A | Filing | Jul 25, 2016 | — |
| F-1/A | Filing | Jul 22, 2016 | — |
| F-1 | Registration statement (foreign issuer) | Jul 7, 2016 | — |
Showing 106 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- QNRX (Nasdaq)
- Incorporated in
- Israel
- Headquarters
- Ashburn, VA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1671502
- Former names
- Quoin Pharmaceuticals, Ltd. (until Sep 1, 2026); Cellect Biotechnology Ltd. (until Oct 15, 2021); Cellect Biomed Ltd. (until Jul 7, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.